No, this is not the cure for all cancer. But it may be the breakthrough that proves doctors can create a vaccine specifically for one person’s cancer and train that patient’s immune system to stop it from returning.

That is the direct meaning of Moderna and Merck’s announcement—and why Moderna’s stock surged more than 120% Wednesday, climbing as much as 156% during trading.

The vaccine does not prevent people from developing cancer. It does not cure every cancer. It does not replace surgery, chemotherapy or radiation. It has not been proven to destroy large tumors or rescue patients with terminal disease.

What it has done is significantly reduce the danger that high-risk melanoma will return or spread after surgeons have removed the visible cancer.

That is a major achievement because cancer often returns through microscopic cells that remain inside the body after surgery. Scans may show that the patient is cancer-free while a small number of hidden cells are still capable of rebuilding the disease months or years later.

Moderna’s experimental vaccine, called intismeran autogene, is designed to help the immune system find and attack those remaining cells before they become another tumor.

The Phase 3 trial included 1,137 patients with stage IIB through stage IV melanoma, the deadliest form of skin cancer. All had undergone surgery to remove their tumors. They received either Merck’s immunotherapy drug Keytruda alone or Keytruda combined with Moderna’s personalized vaccine.

Patients receiving the combination remained cancer-free longer and were less likely to have the disease spread to another part of the body. It was the first successful late-stage trial of a personalized mRNA cancer vaccine.

The treatment is called personalized because there is no single vaccine taken from a shelf.

Doctors begin with the patient’s removed tumor and sequence its genetic material. Computers identify mutations that distinguish the cancer from healthy cells. Moderna then manufactures an individual vaccine containing instructions for as many as 34 targets found inside that patient’s tumor.

The vaccine effectively gives the immune system a “wanted poster” showing what the cancer looks like. Keytruda then removes one of the biological brakes that cancer uses to hide from immune defenses.

The vaccine identifies the target. Keytruda helps release the immune system to attack it.

This is why the breakthrough could eventually extend beyond melanoma. The technology is not designed around one universal melanoma marker; it is designed around the mutations found inside each individual tumor. In theory, doctors could use the same process to build vaccines for patients with lung, kidney, bladder and other cancers.

But theory is not proof.

Cancer is not one illness. It is hundreds of different diseases, and some tumors are much better than others at hiding from the immune system. Success in melanoma does not mean the same vaccine strategy will automatically work in pancreatic, breast, colon, prostate or brain cancer.

Moderna and Merck are running nine Phase 2 and Phase 3 trials across several tumor types, including non-small-cell lung, kidney and bladder cancers. Until those studies succeed, this remains a melanoma breakthrough with broader potential—not a universal cancer solution.

Earlier Phase 2 results showed how meaningful the benefit could be. After five years, the combination reduced the risk of melanoma returning or causing death by 49% and reduced the risk of distant spread or death by 59% compared with Keytruda alone.

The companies have not yet released the corresponding percentages from the larger Phase 3 study. They also have not conclusively proven that the vaccine allows patients to live longer. The complete results must be presented to specialists, reviewed independently and evaluated by regulators.

The treatment also comes with practical challenges. Every patient needs tumor sequencing and a separately manufactured vaccine. The process must be fast enough to begin treatment soon after surgery, scalable enough to serve thousands of patients and affordable enough for insurers and health systems to cover.

Patients must also receive Keytruda, which can cause serious immune reactions by prompting the body to attack healthy organs. The personalized vaccine commonly caused fatigue, injection-site pain and chills in earlier testing, although most vaccine-related reactions were mild or moderate.

For a melanoma patient whose cancer was completely removed but remains at high risk of returning, this could become an important new treatment if regulators approve it—potentially as early as next year.

For someone currently living with another form of cancer, the announcement does not provide an immediate new medicine. It provides evidence that a powerful new method may work and that it can now be tested seriously across other cancers.

Moderna’s extraordinary stock surge reflects that larger possibility. Investors are not valuing only a melanoma treatment. They are betting that the company has validated an entirely new mRNA platform capable of producing individualized cancer vaccines.

So, is this the breakthrough the world has been waiting for?

It is not the final cure that ends cancer. It is the first large, decisive proof that scientists can study one person’s tumor, manufacture a vaccine around its unique mutations and improve that patient’s protection against the cancer returning.

If the approach succeeds in additional tumors, this may be remembered not as the day cancer was cured, but as the day medicine proved it could begin building a different cancer vaccine for every patient.

JBizNews Desk | Cambridge

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.